全文获取类型
收费全文 | 77626篇 |
免费 | 41471篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 1519篇 |
儿科学 | 4252篇 |
妇产科学 | 522篇 |
基础医学 | 15806篇 |
口腔科学 | 5064篇 |
临床医学 | 12448篇 |
内科学 | 23091篇 |
皮肤病学 | 7475篇 |
神经病学 | 13474篇 |
特种医学 | 2202篇 |
外科学 | 13964篇 |
综合类 | 32篇 |
一般理论 | 22篇 |
预防医学 | 4165篇 |
眼科学 | 1275篇 |
药学 | 5658篇 |
中国医学 | 1023篇 |
肿瘤学 | 7126篇 |
出版年
2023年 | 49篇 |
2022年 | 84篇 |
2021年 | 1339篇 |
2020年 | 5075篇 |
2019年 | 10856篇 |
2018年 | 10108篇 |
2017年 | 11472篇 |
2016年 | 12096篇 |
2015年 | 11956篇 |
2014年 | 11868篇 |
2013年 | 12335篇 |
2012年 | 4106篇 |
2011年 | 4084篇 |
2010年 | 8931篇 |
2009年 | 5273篇 |
2008年 | 2066篇 |
2007年 | 913篇 |
2006年 | 955篇 |
2005年 | 743篇 |
2004年 | 726篇 |
2003年 | 770篇 |
2002年 | 837篇 |
2001年 | 795篇 |
2000年 | 718篇 |
1999年 | 292篇 |
1998年 | 56篇 |
1997年 | 44篇 |
1996年 | 34篇 |
1995年 | 40篇 |
1994年 | 30篇 |
1993年 | 25篇 |
1992年 | 38篇 |
1991年 | 28篇 |
1990年 | 24篇 |
1989年 | 31篇 |
1988年 | 36篇 |
1987年 | 23篇 |
1986年 | 21篇 |
1985年 | 28篇 |
1984年 | 17篇 |
1983年 | 23篇 |
1982年 | 10篇 |
1981年 | 13篇 |
1980年 | 12篇 |
1979年 | 10篇 |
1978年 | 10篇 |
1977年 | 12篇 |
1975年 | 12篇 |
1972年 | 13篇 |
1970年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
E. Andrs G. Kaltenbach E. Noel M. Noblet‐Dick A.‐E. Perrin T. Vogel J.‐L. Schlienger M. Berthel J. F. Blickl 《International journal of laboratory hematology》2003,25(3):161-166
Background: It has been suggested that oral cobalamin (vitamin B12) therapy may be an effective therapy for treating cobalamin deficiencies related to food‐cobalamin malabsorption. However, the duration of this treatment was not determined. Patients and method: In an open‐label, nonplacebo study, we studied 30 patients with established cobalamin deficiency related to food‐cobalamin malabsorption, who received between 250 and 1000 μg of oral crystalline cyanocobalamin per day for at least 1 month. Endpoints: Blood counts, serum cobalamin and homocysteine levels were determined at baseline and during the first month of treatment. Results: During the first month of treatment, 87% of the patients normalized their serum cobalamin levels; 100% increased their serum cobalamin levels (mean increase, +167 pg/dl; P < 0.001 compared with baseline); 100% had evidence of medullary regeneration; 100% corrected their initial macrocytosis; and 54% corrected their anemia. All patients had increased hemoglobin levels (mean increase, +0.6 g/dl) and reticulocyte counts (mean increase, +35 × 106/l) and decreased erythrocyte cell volume (mean decrease, 3 fl; all P < 0.05). Conclusion: Our findings suggest that crystalline cyanocobalamin, 250–1000 μg /day, given orally for 1 month, may be an effective treatment for cobalamin deficiencies not related to pernicious anemia. 相似文献
83.
The objective of this study was to compare the clinical and laboratory consequences of left and right displacement of the abomasum (LDA and RDA), short‐ and long‐term survival after surgery and the findings in cows, that could not be cured by omentopexy. Data from 564 cases of displaced abomasum (466 LDA, 98 RDA) were analysed retrospectively. Clinical and laboratory findings were compared between the two manifestations of DA. Survival was assessed after 10 days and after 15 months. Necropsy was carried out on cows that died or were killed. On arrival at the clinic, left displacement of the abomasum (LDA) cows had been recognized as diseased for longer. LDA occurred earlier in lactation, and more cows with right displacement of the abomasum (RDA) were pregnant. Overall clinical symptoms were more severe in RDA than in LDA cows. Heart rate was higher, body temperature was lower, inanition, abnormal faeces and ruminal stasis were more frequent in RDA cows. Leucocyte counts were higher, and potassium and chloride levels were lower in RDA cows. Acetonuria was more frequent in LDA cows. More LDA than RDA cows were released from the clinic as cured (82.0% versus 74.5%). However, survival after the early post‐surgical period was similar for RDA and LDA cows. At necropsy, diseases of the gastrointestinal system were the predominant finding in RDA cows, while in LDA cows, diseases of the liver and other concurrent diseases were more important. 相似文献
84.
85.
86.
R. Kazi V. Prasad R. Venkitaraman C.M. Nutting P. Clarke P. Rhys‐Evans K.J. Harrington 《Clinical otolaryngology》2006,31(6):525-530
Objective: To determine the effects of a total laryngectomy on the swallow and subsequent quality of life in head and neck cancer patients. Design: Cross‐sectional single centre cohort study. Setting: Head and Neck Oncology Unit, Tertiary Referral Unit. Patients: Sixty‐two patients who underwent total laryngectomy at our centre participated in the study. Methods: Subjects were stratified by age, sex, tumour stage, other procedures such as myotomy and nerve re‐implantation. Pharyngectomy, glossectomy, flap reconstruction, neck dissection and previous radio‐ and chemotherapy were also assessed to see if they affected swallow and subsequent quality of life. Main outcome was measured using the MD Anderson Dysphagia Inventory questionnaire. Results: Responses were received from 46 males and 16 females (response rate of 80.5%) with a mean age of 64.7 years (SD 9.4). Median follow‐up in patients was 90 months (range 1–276). The mean MD Anderson Dysphagia Inventory total score in our series of patients was 77.7 (SD 16.6). MD Anderson Dysphagia Inventory global score was 79.4 (SD 22.6), Emotional score was 77.7 (SD 17.8), Functional score 81.3 (SD 15.9) and Physical score was 74.1(SD 18). Statistically significant differences were seen between the emotional scores of glossectomised and non‐glossectomised patients (Mann Whitney, P = 0.04). No significant correlation was seen between the subscale scores and the remaining treatment variables such as age, gender, site, tumour stage, myotomy, nerve implantation, radiotherapy, reconstruction and major complications. Conclusion: This questionnaire study is the largest of its type to assess the swallow of patients who have undergone laryngectomy at a single centre. The overall result confirmed that most patients had a subjectively good swallow. Only glossectomy and the method of PE segment closure were shown to significantly affect swallowing outcomes following surgery. We recommend further work especially prospective studies pre and post surgery using this or similarly validated instruments to fully assess swallow in the laryngectomy population. 相似文献
87.
R. Tazi‐Ahnini A. Cox A. J. G. McDonagh M. J. H. Nicklin F. S. Di Giovine J. M. Timms A. G. Messenger P. Dimitropoulou G. W. Duff M. J. Cork 《International journal of immunogenetics》2002,29(1):25-30
Alopecia areata is an inflammatory hair loss disease with a major genetic component. The presence of focal inflammatory lesions with perifollicular T‐cell infiltrates reflects the importance of local cytokine production in the pathogenesis. In addition to its fundamental pro‐inflammatory role, the interleukin‐1 (IL‐1) system has major effects on hair growth regulation in vitro, with the inhibitory actions of IL‐1α and IL‐1β being opposed by the receptor antagonist IL‐1ra. The novel interleukin‐1 like molecule 1 (IL‐1L1) which has greatest gene sequence homology with IL1RN, the gene encoding IL‐1ra, is another potential IL‐1 antagonist. In view of previous studies suggesting a significant role for IL1RN polymorphisms in the pathogenesis of autoimmune/inflammatory disease, we have analysed polymorphisms of IL‐1ra (IL1RN+2018) and its homologue IL‐1L1 (IL1L1+4734) in a case–control association study on 165 patients and a large number of matched controls. Homozygosity for the rare allele of IL1RN (IL1RN*2) was significantly associated with alopecia areata [odds ratio (OR) = 1.89, 95% CI (1.09, 3.28); P = 0.02], confirming our previous findings of significant association with the IL1RN variable number tandem repeat (VNTR). The results also revealed a novel association involving a polymorphism of the interleukin‐1 receptor antagonist homologue IL1L1 at position + 4734, IL1RN+2018, and alopecia areata. The effect of a genotype combining three copies of the rare alleles at the IL1RN and IL1L1 loci conferred a more than additive increase in the risk of disease compared to IL1RN+2018 or IL1L1+4734 alone [OR 3.37 (1.60, 7.06); P = 0.002], suggesting possible synergy between the IL1RN and IL1L1 genes. This effect was stronger in patients with severe disease (alopecia totalis/universalis) [OR 4.62 (1.87, 11.40), P = 0.0022], and in those with early age at onset (< 20 years) [OR = 6.38 (2.64, 15.42), P = 0.0002]. Our results suggest that these polymorphisms within IL1RN and IL1L1 themselves or a gene in linkage disequilibrium with IL1RN and IL1L1 predispose to the more severe forms of alopecia areata. 相似文献
88.
89.
Patrick Terheyden Jürgen C. Becker Christa Lurz George J. Kahaly Eva‐B. Brcker 《Journal der Deutschen Dermatologischen Gesellschaft》2003,1(1):30-35
Background: Scleromyxoedema is a rare disease of unknown aetiology that is characterized by deposition of mucin and sclerotic induration of the skin; it is associated with paraproteinaemia. Patients suffer from progressive disability due to immobilization and cosmetic disfigurement. Treatment of scleromyxoedema is a therapeutic challenge. The antimalarial hydroxychloroquine has a rapid and reliable effect in reticular erythematous mucinosis. Patients and methods: Four consecutive patients (two women, two men; median age: 50 years) with scleromyxoedema, three of them with IgG λ paraprotein, were treated with hydroxychloroquine. Treatment was initiated with 600 mg p. o. for 10 days, followed by 400 mg for at least 4 weeks, and 200 mg thereafter. Results: Complete remission of skin manifestations was achieved in one patient, whereas three patients achieved a partial remission of 61+, 5 and 25 months' duration. Notably, three patients felt increased mobility and reduced firmness of skin during the first week of treatment, which was reflected in a rapid reduction in dermal thickness. In one patient, dysphagia was reverted as evidenced by normalization of oesophageal clearance. Paraproteinaemia was not influenced at all. Side effects included one case of electroretinogram abnormalities after 19 months of therapy and one case of leucopenia after 3 months. Conclusion: Hydroxychloroquine is an effective form of therapy for scleromyxoedema, leading to rapid and prolonged alleviation of symptoms. 相似文献
90.